Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,596,098
  • Shares Outstanding, K 60,322
  • Annual Sales, $ 1,619 M
  • Annual Income, $ 487,850 K
  • 36-Month Beta 1.17
  • Price/Sales 4.18
  • Price/Cash Flow 9.62
  • Price/Book 2.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 2.66
  • Number of Estimates 1
  • High Estimate 2.66
  • Low Estimate 2.66
  • Prior Year 2.58
  • Growth Rate Est. (year over year) +3.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
119.54 +5.35%
on 02/12/19
131.64 -4.34%
on 02/05/19
-2.07 (-1.62%)
since 01/15/19
3-Month
113.52 +10.93%
on 12/24/18
154.44 -18.46%
on 12/03/18
-17.73 (-12.34%)
since 11/15/18
52-Week
113.52 +10.93%
on 12/24/18
184.00 -31.56%
on 06/20/18
-18.06 (-12.54%)
since 02/15/18

Most Recent Stories

More News
New Research: Key Drivers of Growth for IPG Photonics, Keane Group, Jazz Pharmaceuticals, Tredegar, Carriage Services, and Surgery Partners -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IPG Photonics Corporation...

IPGP : 154.88 (+3.56%)
TG : 17.44 (+2.77%)
JAZZ : 125.93 (+0.49%)
CSV : 19.59 (+2.40%)
SGRY : 13.60 (+3.74%)
FRAC : 11.13 (+3.15%)
Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Anne O'Riordan, Senior Managing Director, Life Sciences of Accenture, was appointed to its Board of Directors, effective February 14, 2019....

JAZZ : 125.93 (+0.49%)
Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019, after the close of the financial markets....

JAZZ : 125.93 (+0.49%)
Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings

Herbalife (HLF) is likely to gain from its direct-selling network, product portfolio and solid volumes. However, unfavorable currency movements and stiff competition may hurt the bottom line.

HLF : 56.79 (-1.98%)
JAZZ : 125.93 (+0.49%)
DOVA : 7.92 (+4.62%)
PCRX : 40.68 (+2.52%)
Jazz Inks Deal with Codiak to Develop Exosome Therapeutics

Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.

JAZZ : 125.93 (+0.49%)
MYGN : 31.46 (+1.78%)
EDIT : 20.08 (+1.11%)
INO : 3.70 (+0.27%)
Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Codiak BioSciences, Inc. today announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization...

JAZZ : 125.93 (+0.49%)
Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA

Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.

AVDL : 2.18 (+10.10%)
JAZZ : 125.93 (+0.49%)
NVS : 89.88 (+0.97%)
BLCM : 3.17 (+0.96%)
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment...

JAZZ : 125.93 (+0.49%)
Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 7

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

JAZZ : 125.93 (+0.49%)
JPM : 105.55 (+3.06%)
Jazz (JAZZ) Increases Share Buyback Authorization by $400M

Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.

MLNT : 1.38 (-7.38%)
JAZZ : 125.93 (+0.49%)
HKMPF : 22.5000 (+10.57%)
BSTC : 71.62 (+5.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade JAZZ with:

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 127.87
1st Resistance Point 126.90
Last Price 125.93
1st Support Level 125.29
2nd Support Level 124.65

See More

52-Week High 184.00
Fibonacci 61.8% 157.08
Fibonacci 50% 148.76
Fibonacci 38.2% 140.44
Last Price 125.93
52-Week Low 113.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar